Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,845.20
(
-0.46%
)
Dow Jones
45,960.11
(
0.00%
)
Brent Oil
104.54
(
3.84%
)
Bitcoin
66,669.10
(
-3.08%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 220440

Thursday, 08/09/2018 7:22:29 PM

Thursday, August 09, 2018 7:22:29 PM

Post# of 257295

ENTA—The real disappointment probably was Abbvie's slowdown in [HCV sales]...

This shouldn’t have been a big shock to anyone insofar as ABBV had guided to $3.5B in 2018 HCV sales on its April CC (#msg-140324864). $3.5B is less than the $3.7B (4x$919M) annualized run rate in 1Q18, so a QoQ decline in HCV sales at some point during 2018 was already baked into the guidance.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today